Guerbet SA - Company Profile
Powered by 
All the sales intelligence you need on Guerbet SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Guerbet SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Guerbet SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Guerbet SA (Guerbet) is a manufacturer of contrast agents. The company provides a wide range of imaging products, solutions, and services for Computed Tomography (CT)/Cath Lab examinations, magnetic resonance imaging (MRI), and interventional imaging. CT/Cath Lab contrast agents consist of iodinated active ingredients, and a few examinations of the digestive tract use barium-based products. MRI imaging uses gadolinium complexes. Guerbet has a presence in Europe, Asia, and North and South America. The company offers products directly through its sales structure, distributors, and license holders. Guerbet is headquartered in Villepinte, France.
Headquarters
France
Address
15 Rue Des Vanesses, Zone Paris Nord Ii, Villepinte, Ile-de-France, 93420
Website
www.guerbet.com
Telephone
33 1 45915000
No of Employees
2,746
Industry
Medical Equipment
Ticker Symbol & Exchange
GBT (EPA)
Revenue (2024)
$887.3M
-6.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-773.6%
(2024 vs 2023)
Market Cap*
$110.1M
Net Profit Margin (2024)
XYZ
-820.9%
(2024 vs 2023)
* As of and is in US$
Guerbet SA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Diagnostic Imaging | OptiVantage |
| MRI Contrast Agents | Illumena Neo |
| X-Ray Contrast Agents | OptiOne |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Asset Disposal | In January, the company sold certain assets of Accurate Medical Therapeutics to Argon Medical. |
| 2024 | Regulatory Approval | In September, the company along with Intrasense received the CE marking of DUOnco Liver, an artificial intelligence algorithm designed to detect focal liver lesions. |
| 2024 | Contracts/Agreements | In May, the company entered into a partnership with Nuclidium to support the advancement of targeted copper-based radiotheranostic. |
Competitor Comparison
| Key Parameters | Guerbet SA | GE HealthCare Technologies Inc | Boston Scientific Corp | Merit Medical Systems Inc | ulrich GmbH & Co KG |
|---|---|---|---|---|---|
| Headquarters | France | United States of America | United States of America | United States of America | Germany |
| City | Villepinte | Chicago | Marlborough | South Jordan | Ulm |
| State/Province | Ile-de-France | Illinois | Massachusetts | Utah | Baden-Wurttemberg |
| No. of Employees | 2,746 | 54,000 | 59,000 | 7,500 | 600 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Antoine Fady | Chairman | Executive Board | 2026 | - |
| Karim Boussebaa | Chief Executive Officer | Senior Management | 2026 | - |
| David Hale | Chief Executive Officer | Senior Management | 2022 | 58 |
| Jerome Estampes | Chief Financial Officer; Senior Vice President - Business Development & licensing | Senior Management | - | - |
| Francois Nicolas | Senior Vice President - R&D, Innovation and AI | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer